冠昊生物收盘下跌2.34%，滚动市盈率158.86倍，总市值44.31亿元

Core Viewpoint - Guanhao Bio's stock closed at 16.71 yuan, down 2.34%, with a rolling PE ratio of 158.86 times, indicating a high valuation compared to the industry average [1] Company Overview - Guanhao Bio focuses on developing new products and technologies with independent intellectual property rights, aiming to enhance product quality and optimize product structure as core drivers of development [2] - The main products include biological dura (spinal) membrane patches, chest repair membranes, sterile biological dressings, and corneal implants [2] - The company is recognized as a "National Intellectual Property Advantage Enterprise" and has several subsidiaries classified as high-tech enterprises [2] Financial Performance - In Q1 2025, Guanhao Bio reported revenue of 94.79 million yuan, a year-on-year increase of 3.67%, and a net profit of 14.87 million yuan, also up 3.30%, with a gross profit margin of 77.05% [2] Industry Comparison - The average PE ratio for the medical device industry is 53.47 times, with a median of 37.00 times, positioning Guanhao Bio at the 111th rank within the industry [1][3] - The company's market capitalization stands at 4.431 billion yuan, significantly higher than the industry median market cap of 1.51 billion yuan [3]